Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Impairment expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zomedica

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Its TRUFORMA biosensor platform is designed to assist practitioners in the diagnosis of complex conditions. The company was founded by Gerald L. Solensky. on January 7, 2013 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zomedica reports revenue growth and product advancements amidst profitability challenges

Zomedica's 2022 performance reflects revenue growth and product advancements, though challenges in profitability persist. The company's strategic focus on companion animal healthcare presents growth opportunities through innovation and market stability. Addressing expense management, stock stability, and leveraging market trends will be key for Zomedica's future success.

Zomedica reports robust Q1 earnings, eyes global equine market

Zomedica's Q1 2023 showcased strong revenue growth, particularly driven by TRUFORMA and international sales.
The company's focus on maintaining margins, expanding marketing efforts, and targeting global equine markets positions it for future success.
Challenges include the closure of the cancer assay program and operational hurdles in achieving the 70% gross margin target.
Opportunities lie in the launch of new assays, international expansion, and investor engagement beyond quarterly updates.

Zomedica reports robust Q2 earnings, eyes international expansion and product launches

Zomedica's Q2 performance reflects strong revenue growth and strategic investments for future profitability.
Despite challenges like increased OpEx and lower margins, the company is focused on long-term growth through product launches and market expansion.
Opportunities lie in international market exploration, upcoming product launches, and investor engagement strategies.

Zomedica reports record revenues, eyes global expansion amidst stock challenges

Zomedica's Q3 performance reflects strong revenue growth and strategic acquisitions, despite facing challenges like potential delisting and net losses.
The company's focus on new product launches, international expansion, and partnerships presents opportunities for future growth and market diversification.
Overall, Zomedica aims to drive towards cash flow breakeven by leveraging innovative products and maintaining a strong liquidity position.

Zomedica reports record revenues, eyes profitability through strategic growth

Zomedica's strong financial performance in Q4 2023 and full-year results, coupled with a robust cash position and strategic growth initiatives, position the company for future success.
While facing challenges related to compliance requirements and integration costs, Zomedica's focus on innovation, market expansion, and profitability goals present opportunities for sustained growth.
By balancing operational efficiency, product development, and financial discipline, Zomedica aims to drive revenue growth, enhance market presence, and deliver long-term value to shareholders.

Zomedica reports revenue growth and strong cash position in Q1

Zomedica's Q1 2024 performance showed revenue growth driven by key segments, strong cash position, and focus on operational efficiency. The company faces challenges in managing expenses and achieving aggressive revenue targets. Opportunities lie in expanding product lines, international sales, and maintaining financial strength.

Zomedica reports Q2 revenue growth amidst challenges and opportunities

Zomedica's Q2 performance showed revenue growth but with challenges in sales force and noncash charges.
Strengths include achieving milestones and expanding facilities, while opportunities lie in international expansion.
The company faces the task of managing cash burn and finding a new CFO.
Expectations for the second half of 2024 include revenue growth and operational focus.

Zomedica reports record Q3 revenue, eyes global expansion opportunities

Zomedica's Q3 2024 performance showcased revenue growth, margin strength, and cost reduction efforts, positioning the company for future profitability. Strategic international partnerships and product innovations underscore growth potential.
While challenges in achieving profitability persist, Zomedica's focus on operational efficiency and global expansion presents opportunities for sustained growth. Addressing investor inquiries and executing on strategic initiatives will be key to unlocking future value.
With a solid cash position, ongoing product enhancements, and expansion into new markets, Zomedica is poised for growth. Clear communication on financial targets, operational milestones, and strategic direction will be crucial for investor confidence and market success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The stock price of Zomedica Corp (NYSEAMERICAN: ZOM) increased by 95.6% this past week. This is why it happened.

ZOM Stock Price Increased 95.6% This Past Week: Why It Happened

ZOM stock has skyrocketed in a matter of months. While there can be some optimism, valuation after the rally suggests more caution.

Zomedica Is a High-Risk Trade, Not a Long-Term Investment

WallStreetBets traders may have found their next target.

Why Zomedica Stock Surged Today

ZOM stock is on the move once again, as investors bid up Zomedica shares. Here's what you should know right now.

ZOM Stock: 2 Big Reasons Zomedica Shares Are Soaring Today

ZOM stock is a speculative buy for several reasons including leaning into a solid, growing market. Now all investors need to wait for is a product.

Here's Why Zomedica Stock Is Less Speculative Than You Might Think

ZOM stock is an all-or-nothing proposition, but there's reason to believe that its breathtaking rally is nowhere near the finish line. The post $1 Is Just the First Stop in a Long Journey for Zomedica Stock appeared first on InvestorPlace.

$1 Is Just the First Stop in a Long Journey for Zomedica Stock

Chewy

Freshpet

IDEXX Laboratories

PetIQ

PetMed Express

Trupanion

Pet stocks have performed very well recently, and many analysts believe that this trend will continue as the industry grows. The post 7 Pet Stocks for Animal Lovers and Investors Alike appeared first on InvestorPlace.

7 Pet Stocks for Animal Lovers and Investors Alike

Zomedica has a permanent CEO, a new distribution deal and a product that is getting a lot of attention. Can ZOM stock enter the mainstream?

Devotion to Pets Will Likely Drive Zomedica Higher

ZOM stock surged due to a surprising social media endorsement. However, Zomedica has a real commercial product to launch as well.

Zomedica Has More Than Just ‘Tiger King' Hype to Boost Shares

There's a lot of hype around ZOM stock these days, but the name could prove to be a growth star among pet-related equities. The post Believe It or Not, There's Something to See With Zomedica appeared first on InvestorPlace.

Believe It or Not, There's Something to See With Zomedica

American Battery Technology Company

Guardion Health Sciences Inc

ObsEva

Safe Bulkers

IsoRay

There's an old saying that 'gaps refill'. And that means that these 7 penny stock Bubbles may be about to burst.

7 Penny Stock Bubbles That Are About to Burst

Zomedica looks like it will be a winner once its pet lab product launches. ZOM stock could be worth $2 or more if it can garner 10% of the pet diagnostic lab market share.

Zomedica May Be a Winner Once Its Pet Lab Product Launches

The stock price of Zomedica Corp (NYSEAMERICAN: ZOM) is trading at over 18% pre-market. This is why it happened.

ZOM Stock Price Increases Over 18% Pre-Market: Why It Happened

ANN ARBOR, Mich., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that it has signed an agreement with Miller Veterinary Supply (“Miller”) for the distribution of TRUFORMA™, Zomedica's first product, planned to begin sales on March 30, 2021.

Zomedica Signs TRUFORMA™ Distribution Agreement With Miller Veterinary Supply

Zomedica Pharmaceuticals is likely a pump-and-dump. Don't get caught holding the bag when ZOM stock crashes back to under $1 per share.

Zomedica Pharmaceuticals Is Mostly Hype

Investors are intrigued by the popular penny stock's new razor and blade strategy.

Why Zomedica Stock Jumped Today

The stock price of Zomedica Corp (NYSEAMERICAN: ZOM) is trading at more than 19% during pre-market hours. This is why it happened.

ZOM Stock Price Jumps Over 19% Pre-Market: Why It Happened

Zomedica shares are surging after the company updated investors on a warrant-redemption cash influx and news that its end-of-March product rollout is on track. Pet-related stocks are hot and ZOM may be on the verge of a significant breakout.

ZOM Stock: Why Zomedica Shares Are on the Move Again Today

ANN ARBOR, Mich., Jan. 18, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today issued the following letter from Robert Cohen, Chief Executive Officer, updating Zomedica's shareholders regarding several key activities and events:

Zomedica CEO Issues Shareholder Letter as TRUFORMA™ Nears Commercialization

Even with the company addressing a potentially hyper-growth market, the price action of ZOM stock is just too frothy. The post Expect This Pullback in High-Flying Zomedica Pharmaceuticals Stock to Continue appeared first on InvestorPlace.

Expect This Pullback in High-Flying Zomedica Pharmaceuticals Stock to Continue

A booming market for pet care could push this soaring stock even higher.

Should You Buy Zomedica Stock Right Now?

Zomedica is a development-stage company that focuses on the unmet diagnostic and therapeutic treatment needs of clinical veterinarians. The company's first product - TRUFORMA - is an innovative diagnostic tool that is scheduled for commercial launch on March 31, 2021.

Zomedica Nears Major Catalyst In TRUFORMA Product Launch

ZOM stock continues to rocket higher. Here's what you should know about the red-hot pet care play Zomedica now.

ZOM Stock: 12 Things to Know as Zomedica Shares Rocket Higher

The pet care company's new diagnostic platform could be a game changer.

Why Zomedica Stock Skyrocketed More Than 100% Today

A penny stock popped Monday and “Tiger King” star Carole Baskin could be the reason. What Happened: A video on YouTube shows Baskin discussing Zomedica Corp (NYSE: ZOM) and the company's upcoming Truforma point of care diagnostic product to all the “cool cats and kittens” watching.

News for Zomedica Stock (ZOM)